Stéphane H.
- Country
- Belgium
- Department
- Oncology and Hematology
Research Overview
- Phase I/IIa Study of Inhaled CIS-DPI as Adjunctive Therapy in Stage IV Non-Small Cell Lung Cancer Patients
- Tarlatamab plus Durvalumab versus Durvalumab Alone in Patients with Extensive-Stage Small Cell Lung Cancer Following Platinum-Etoposide Therapy
- Phase III Randomized Study of Lurbinectedin Alone or with Irinotecan Versus Topotecan or Irinotecan in Relapsed Small Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 173 of 383 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) treatment approaches. Their expertise extends to both early-stage resectable cases and advanced metastatic disease.
- Resectable NSCLC Stage IIA to IIIB
- Metastatic nonsquamous NSCLC
- Relapsed SCLC
The investigator works with novel therapeutic strategies including immunotherapy combinations and targeted treatments.
Therapeutic Approaches
The investigator focuses on innovative treatment combinations involving immunotherapy, targeted therapies, and chemotherapy for lung cancer patients.
- Pre- and post-surgical treatments
- Combination therapy strategies
- Advanced stage treatment protocols
Their research encompasses both established treatment modalities and experimental therapeutic agents.
Advanced Cancer Studies
The investigator conducts research in advanced solid tumors with a particular focus on novel drug combinations and treatment strategies.
- First-line metastatic treatments
- Drug resistance management
- Innovative therapy combinations
Their work includes evaluation of treatment efficacy in various stages of disease progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.